UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 394

Sortiert nach

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas

Nature communications, 2015-01, Vol.6 (1), Article 6140

2015

Link zum Volltext

Verfügbarkeit prüfen

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Nature (London), 2017-06, Vol.546 (7658), p.431-435

2017

Link zum Volltext

Verfügbarkeit prüfen

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Cell, 2019-08, Vol.178 (4), p.933-948.e14

2019

Link zum Volltext

Verfügbarkeit prüfen

A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer

Cancer cell, 2014-09, Vol.26 (3), p.344-357

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer

American journal of human genetics, 2016-05, Vol.98 (5), p.801-817

2016

Link zum Volltext

Verfügbarkeit prüfen

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Nature communications, 2017-08, Vol.8 (1), p.319-11, Article 319

2017

Link zum Volltext

Verfügbarkeit prüfen

CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing

Genome Biology, 2018-11, Vol.19 (1), p.202-202, Article 202

2018

Link zum Volltext

Verfügbarkeit prüfen

Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background

Cancer genetics, 2012-01, Vol.205 (1), p.1-11

2012

Link zum Volltext

Verfügbarkeit prüfen

Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)

Genetics in medicine, 2020-07, Vol.22 (7), p.1142-1148

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer

Clinical cancer research, 2019-07, Vol.25 (14), p.4363-4374

2019

Link zum Volltext

Verfügbarkeit prüfen

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (7), p.2750-2760

2011

Link zum Volltext

Verfügbarkeit prüfen

A human breast atlas integrating single-cell proteomics and transcriptomics

Developmental cell, 2022-06, Vol.57 (11), p.1400-1420.e7

2022

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy at large: the road to personalized cancer vaccines

Nature medicine, 2013-09, Vol.19 (9), p.1098-1100

2013

Link zum Volltext

Verfügbarkeit prüfen

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target

Clinical cancer research, 2014-11, Vol.20 (21), p.5537-5546

2014

Link zum Volltext

Verfügbarkeit prüfen

Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood

Clinical cancer research, 2017-07, Vol.23 (13), p.e107-e114

2017

Link zum Volltext

Verfügbarkeit prüfen

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer

Nature genetics, 2009-07, Vol.41 (7), p.811-815

2009

Link zum Volltext

Verfügbarkeit prüfen

Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Clinical cancer research, 2017-07, Vol.23 (13), p.e123-e132

2017

Link zum Volltext

Verfügbarkeit prüfen

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer

Cancer immunology research, 2018-03, Vol.6 (3), p.276-287

2018

Link zum Volltext

Verfügbarkeit prüfen

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

Clinical cancer research, 2008-01, Vol.14 (1), p.230-239

2008

Link zum Volltext

Verfügbarkeit prüfen

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

Nature communications, 2022-11, Vol.13 (1), p.6728-6728, Article 6728

2022

Link zum Volltext

Verfügbarkeit prüfen

HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (34), p.14391-14396

2009

Link zum Volltext

Verfügbarkeit prüfen

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

Nature medicine, 2011-08, Vol.17 (8), p.941-943

2011

Link zum Volltext

Verfügbarkeit prüfen

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

PloS one, 2013-03, Vol.8 (3), p.e59588

2013

Link zum Volltext

Verfügbarkeit prüfen

Lower abdominal and pelvic radiation and testicular germ cell tumor risk

PloS one, 2020-11, Vol.15 (11), p.e0239321

2020

Link zum Volltext

Verfügbarkeit prüfen

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2876-2883

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 394

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(375)
Mit Volltextzugriff
(360)

Publikationsform

Sprache

Englisch
(393)
Japanisch
(51)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer

Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing

Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background

Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

A human breast atlas integrating single-cell proteomics and transcriptomics

Immunotherapy at large: the road to personalized cancer vaccines

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target

Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer

Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

Lower abdominal and pelvic radiation and testicular germ cell tumor risk

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Suchergebnisse filtern